Trine Stokstad1,2, Sveinung Sørhaug3,4, Tore Amundsen3,4, Bjørn H Grønberg5,6. 1. Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, NTNU, Norwegian University of Science and Technology, Trondheim, Norway. 2. Department of Gynecology, St. Olav's Hospital, Trondheim University Hospital, Trondheim, Norway. 3. Department of Circulation and Medical Imaging, Faculty of Medicine and Health Sciences, NTNU, Norwegian University of Science and Technology, Trondheim, Norway. 4. Department of Thoracic Medicine, St. Olav's Hospital, Trondheim University Hospital, Trondheim, Norway. 5. Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, NTNU, Norwegian University of Science and Technology, Trondheim, Norway; bjorn.h.gronberg@ntnu.no. 6. Department of Oncology, St. Olav's Hospital, Trondheim University Hospital, Trondheim, Norway.
Abstract
BACKGROUND: Time-to-treatment is defined as a quality indicator for cancer care but is not well documented. We investigated whether meeting Norwegian timeframes of 35/42 days from referral until start of chemotherapy or surgery/radiotherapy for lung cancer was associated with survival. PATIENTS AND METHODS: The medical records of 439 lung cancer patients at a regional cancer center were reviewed and categorized according to treatment: (i) surgery; ii) radical radiotherapy; iii) stereotactic radiotherapy; iv) palliative treatment, no cancer symptoms; v) palliative treatment with severe cancer symptoms). RESULTS: Proportions receiving timely treatment varied significantly at 39%, 48%, 10%, 44% and 89%, respectively (p<0.001). Overall, those starting treatment on time had the shortest median overall survival (10.6 vs. 22.6 months; p<0.001). This was also the case for palliative (5.3 vs. 11.4 months) (p<0.001) but not for curative treatment (not reached vs. 38.3 months) (p=0.038). CONCLUSION: Timely treatment is not necessarily associated with improved survival. Copyright
BACKGROUND: Time-to-treatment is defined as a quality indicator for cancer care but is not well documented. We investigated whether meeting Norwegian timeframes of 35/42 days from referral until start of chemotherapy or surgery/radiotherapy for lung cancer was associated with survival. PATIENTS AND METHODS: The medical records of 439 lung cancer patients at a regional cancer center were reviewed and categorized according to treatment: (i) surgery; ii) radical radiotherapy; iii) stereotactic radiotherapy; iv) palliative treatment, no cancer symptoms; v) palliative treatment with severe cancer symptoms). RESULTS: Proportions receiving timely treatment varied significantly at 39%, 48%, 10%, 44% and 89%, respectively (p<0.001). Overall, those starting treatment on time had the shortest median overall survival (10.6 vs. 22.6 months; p<0.001). This was also the case for palliative (5.3 vs. 11.4 months) (p<0.001) but not for curative treatment (not reached vs. 38.3 months) (p=0.038). CONCLUSION: Timely treatment is not necessarily associated with improved survival. Copyright
Authors: Nasiruddin Mohammed; Larry Llyn Kestin; Inga Siiner Grills; Madhu Battu; Dwight Lamar Fitch; Ching-Yee Oliver Wong; Jeffrey Harold Margolis; Gary William Chmielewski; Robert James Welsh Journal: Int J Radiat Oncol Biol Phys Date: 2010-05-13 Impact factor: 7.038
Authors: Jarrod T Bullard; Jan M Eberth; Amanda K Arrington; Swann A Adams; Xi Cheng; Ramzi G Salloum Journal: South Med J Date: 2017-02 Impact factor: 0.954
Authors: R D Neal; P Tharmanathan; B France; N U Din; S Cotton; J Fallon-Ferguson; W Hamilton; A Hendry; M Hendry; R Lewis; U Macleod; E D Mitchell; M Pickett; T Rai; K Shaw; N Stuart; M L Tørring; C Wilkinson; B Williams; N Williams; J Emery Journal: Br J Cancer Date: 2015-03-31 Impact factor: 7.640